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ABSTRACT
INTRODUCTION: In the last 5 years, the use of automatic insulin delivery systems has been increasing 
among patients with type 1 diabetes mellitus (T1DM). It has been shown that they improve metabolic 
control, decrease the time spent in hypoglycemia and the number of episodes of nocturnal hypoglycemia; 
increase the time spent in target and are feasible and safe. 
AIM: Our aim is to evaluate the glycemic control in children/adolescents using do-it-yourself (DIY) 
regulatory unapproved insulin-delivery loops vs sensor-augmented pump therapy (SAP).
MATERIALS AND METHODS: A total of 43 families with child/children with T1DM on pump treatment 
and continuous use of continuous glucose monitoring (CGM) were invited to participate in the study; 31 
(72.1%) of the families accepted. The children were followed for 6 months, a total of 196 patient months.
RESULTS: The study group consisted of 31 children with T1DM, 24 (77.4%) of them were on SAP, and 7 
(22.6%) used DIY loops. No differences were observed in regard to age, duration of diabetes, and daily insulin 
dose between groups. Patients on DIY loops spent significantly more time in range (83.0 vs 68.8%, p=0.02), 
less time in hyperglycemia above 14 mmol/L (2.1 vs 8.6%, p=0.02). They had significantly better HbA1c at 
the 6th month (6.5 vs 7.2%, p=0.006) vs SAP patients for the follow-up period. No severe hypoglycemia and 
diabetic ketoacidosis (DKA) occurred. There were no gender differences between and within both groups.
CONCLUSION: DIY unregistered loop systems showed promising results for better metabolic control at 
least in terms of mean blood glucose levels (BGLs) and without increasing the risk of severe hypoglycemia 
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and DKA. Further impact e. g. mean insulin dose, 
long-term efficacy, consumed fat/protein in the 
daily diets, etc., remains to be studied in future 
larger and longer studies.
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control leads to dissatisfaction and increased burden 
among young people with T1DM, their families, and 
caregivers (14,15). Recently published papers showed 
higher incidence of anger, depression, and other psy-
chiatric disorders among adolescents with diabetes 
(16,17). As a consequence, the  quality of life among 
these age group and their families is lower (18,19). 
The trend of the increasing incidence of T1DM by 
3.4%, annually in the pediatric population (20) and 
suboptimal metabolic control are the main prereq-
uisites for the progress in automatic insulin delivery 
systems.
All known benefits of the hybrid closed loops 
in terms of metabolic control and reduction of blood 
glucose level (BGL) variability, as well as the reduced 
number of acute complications of T1DM, turn them 
into an innovative, efficacious and safe approach for 
treating children and adoslecents (21,22).
The history of  Do-it-yourself loop systems 
(DIYs) started with John Costik in 2013, the father of 
a child with a T1DM, who began to monitor remote-
ly data from his son‘s sensor. He managed to down-
load the data from the CGM to a local computer and 
forwarded it to the cloud. At the next level, Ben West, 
an engineer developing software for insulin pumps, 
managed to create an algorithm, which changed in-
sulin infusion rates according to BG data from the 
sensor. He succeeded to „close the loop“ and to co-
define a platform called Open Source of Artificial 
Pancreas (OpenAPS, December 2014) (23,24). DIY 
systems are HCLS, but have not been approved by the 
legal authorities. In order to ensure the safety of pa-
tients who use it in case of technical problems, when 
the algorithm stops working, the DIY system returns 
to basic basal-bolus regime of insulin pump therapy. 
Another difference, compared to HCLS, is that us-
ers themselves choose the brands of devices, which 
are connected in a closed loop system (pumps, CGM, 
smart phones and settings) (25,26). The first results 
for the OpenAPS advantages were self-reported by 
users and showed a beneficial effect in terms of de-
creased HbA1c (from 7.1% to 6.2%), increased time in 
range (TIR) (from 58% to 81%), improved sleep qual-
ity and satisfaction (27). The same team published in 
2018 a retrospective analysis of data before and after 
initiation of DIY’s and confirmed the benefits of the 
system even in patients with good control, and the 
time spent in hypoglycemia and the BGL variability 
INTRODUCTION
Automatic insulin delivery systems consist of: 
insulin pump (CSII), continuous glucose monitoring 
(CGM, sensor) and an algorithm that controls the re-
quired amount of the hormone. There are two types 
of loops: single hormone systems, which work only 
with fast-acting insulin analogues, and dual-hor-
mone systems, which use insulin and glucagon. Sen-
sor-augumented pump therapy (SAP) marks the be-
ginning of the closing of the loop. The first step was 
the creation of the Minimed Paradigm Real Time 
System (insulin pump and sensor), which had the 
unique for that time function to stop automatically 
insulin infusion at a set in advance hypoglycemic val-
ue (1). Subsequent developments were based on pre-
dictive models that stop the supply of insulin before 
hypoglycaemia is reached and automatically restart 
insulin delivery with the rise of blood glucose (BG) 
up to pre-determined levels (Mimimed 640G with 
Smart Guard, Tandem Basal-IQ PLGS System) (2). 
Hybrid closed loop systems (HCLS) control, in auto-
mated mode, basal insulin rates according to the real 
time requirements. Additional boluses for the carbo-
hydrate intake are still introduced manually. Quickly 
developing technological advances in the treatment 
of diabetes have led to the approval by FDA of two 
HCLS: MiniMed 670 G in 2017 and Tandem Con-
trol-IQ algorithm with an insulin pump t:slim X2 in 
2019 (3,4).
Progress in the development of automatic insu-
lin systems is aimed at achieving optimal metabol-
ic control, as it is known that good metabolic con-
trol reduces the long-term complications of type 1 di-
abetes mellitus (T1DM) (5-8) as well as episodes of 
acute severe hypoglycaemia and diabetic ketoacido-
sis (8,9). Despite the increasing introduction of new 
technologies and innovations in the treatment of 
T1DM (pumps, sensors, etc.), only one third of chil-
dren and adolescents with T1DM in the U.S.A. meet 
the HbA1 target of less than 7.5% (58 mmol/mol)
(10). Foster et al. published the latest results from the 
T1DM Exchange registry, which indicated that only 
17% of patients achieved the goal (11). According to 
the last available report from the SWEET database, 
only 26.1% of children and adolescents cover the In-
ternational Society for Pediatric and Adolescent Dia-
betes (ISPAD) criteria for HbA1c < 7.0% (<53 mmol/
mol) (12,13). It is known that suboptimal diabetes 
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were reduced (26, 27). At the best of the authors’ cur-
rent knowledge, only one scientific article about the 
benefits of OpenAPS in childhood is published by a 
Korean group (28).
AIM
The aim of the current study is to evaluate the 
glycemic control in children/adolescents using DIY’s 
regulatory unapproved insulin-delivery loops vs sen-
sor-augmented pump therapy (SAP). 
MATERIALS AND METHODS
The study was conducted at the First Pediatric 
Clinic and CITAT-D (Center for Innovation Thera-
pies and Advanced Technologies in Diabetes) at St. 
Marina University Hospital, Varna, Bulgaria for a 
6-month period (196 patient/months of follow-up). 
All CITAT-D patients with T1DM from 0 to 18 years 
of age were invited to the study. All of them had used 
pump therapy with CGM for at least 6 months, which 
amounted to 43. Out of the 43 contacted families, 31 
(77.4%) paricipants were included in the study after 
obtained parental consent for all the procedures. Ed-
ucational sessions about the study protocol were de-
livered. Written instructions were provided to the 
families, including the minimal time of sensor us-
age (>70% for 10 to 14 days) before the scheduled vis-
its (0-3-6 months). Participants were instructed to 
contact the team in case of technical problems with 
the devices. Recommendations were supplied about 
the place of insertion of the sensors according to the 
manufacturer‘s specification. Data from sensor de-
vices were downloaded through the respective pro-
grams and saved in an electronic file (CVS and pdf) 
and/or paper version. Three types of sensors were 
used (FreeStyle Libre, Dexcom, EnLite 2.0). The data 
from the last 10-14 days before the day of the sched-
uled visit were analyzed. In the framework of the 
study, the following indicators were evaluated: 
  Sensor usage (in % of time);
  Time in range (TIR) - BGL 3.9-10 mmol/L;
  Time spent in hypoglycemia (BGL <3.9 
mmol/L); 
  Time spent on significant hyperglycaemia (BGL 
>14.0 mmol/L);
  Coefficient of variability of BGLs (CV%).
Some of the internationally recommended pa-
rameters for assessment of metabolic control (time 
with BG <3.0 mmol/L, BG >10 mmol/L, average 
BGLs and glucose management index) were not 
measured due to the technical obstacles linked to the 
lack of official registration of 2 of the sensors in our 
country. 
All participants underwent a full clinical ex-
amination at baseline and at the end of the study 
(6th month), with particular attention to the clini-
cal data of acute and/or exacerbated chronic inflam-
matory processes, signs of growth and development 
derangements. On the day of the physical examina-
tions, by protocol, participants came to the clinic in 
the morning at fast for the routine procedures: height 
and weight measurements, waist circumference, ar-
terial pressure, insulin application sites and assess-
ment of pubertal development (done by one inves-
tigator only). The mean daily insulin dose was de-
termined from downloaded reports of the insulin 
pumps and/or the logs kept by the parents for the last 
14 days before the visit. 
Sample Collection 
For the whole period of the study two fasting 
blood samples were taken at baseline and at the 6th 
month for determing HbA1c. The parameter was de-
termined by the reference immunobiodimetric in-
hibitory method in the central clinical laboratory of 
St. Marina University Hospital, Varna. During the 
study period, the laboratory participated in external 
and national laboratory control for HbA1c. The “cut 
off” of Hb1c% for good metabolic control until 2018 
was <7.5%. After the 2018 publication of the ISPAD 
Clinical Consensus Statement, the target value was 
changed to <7.0%, which is routinely written in all 
patient documentation (patient file, discharge letters, 
outpatient visits records, etc.). 
Statistical Analysis 
Statistical analysis was performed using SPSS 
for Windows ver. 19. Descriptive analysis was ap-
plied. Logistic regression models were used to ana-
lyze correlations between TIR, time in hypoglyce-
mia/hyperglycemia, HbA1c, and the type of the in-
sulin therapy. Statistically significant differences 
were accepted if p≤0.05.
RESULTS
Twenty-four (77.4%) of all participants (n=31) 
used SAP and the remaining seven (22.6%) - DIYs 
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(OpenAPS, Loop). No significant differences were 
observed between the two groups in terms of age, 
gender, daily insulin dose, and achieved control be-
fore CGM (Table 1).
Participants on DIY systems  spent  signifi-
cantly less time in hyperglycemia >14 mmol/L (5.9 vs 
8.7%, p = 0.02) (Fig. 2).
Despite the lack of statistical significance, the 
same trend was observed for the time in hypoglyce-
mia. In the DIY group, the average time spent with 
BGL <3.9 mmol/L was twice as low as that in the SAP 
group (4.5% vs 7.3%, p = 0.4). The time with BGL <3.5 
mmol/L in both groups decreased during follow-up, 
predominantly for SAP users  (from 3.5% at baseline 
to 1.3%) (Fig. 3). 
The DIY group achieved significantly bet-
ter metabolic control compared to SAP: baseline 
HbA1c - 6.25±0.9% vs 7.2±0.9%  (p<0.001) and 6th 
month HbA1c - 6.5±0.4% vs 7.2±1.0% (p=0.006), 
respectively. 
In all subjects, the coefficient of variability (CV) 
was below the upper limit of 36%. No significant dif-
ferences were found between groups: DIYs vs SAP 
baseline 25% vs 30%; 6th month 27% vs 27.5%, NS.
DISSCUSSION 
DIY’s show promising results in achieving op-
timal diabetes care in children and adolescents. The 
evidence of advantages of the automatic insulin de-
livery systems from the current study are compara-
ble to those published globally (23-28). The benefits 
of the closed loop systems in the treatment of T1DM 
  SAP DIY Loops p
Age (y.) 9.1±2.0 10.1±2.0 NS
Gender (girls, %) 43% 29% NS
Duration T1D (y.) 4.92±2.0 5.03±1.7 NS
Insulin dose(U/kg/d)      
     initial 0.83±0.2 0.76±0.2 NS
     final 0.75±0.2 0.79±0.2 NS
HbA1c  before CGM (%) 7.24±0.8 6.97±1.2 NS
Table 1. Demographic characteristics of the participants The group of closed loops spent significantly more time in range 
compared to SAP. The trend was consistent throughout the entire observation period (82.3% vs 68%, p=0.0002).  In-
creased TIR was more pronounced at the 3rd and 6th month for the follow-up period, which is demonstrated on Fig. 1.
Fig. 1. Time in range trends
Fig. 2. Time spent in hyperglycemia above 14 mmol/L. 
Comparison between SAP and DIYs
Fig. 3. Distribution of hypoglycemia
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in the studied group include optimal control, stable 
BGLs and reduced time spent in hypo- and hyper-
glycemia. The DIY group covers the latest global cri-
teria for good diabetes control: CGM use >70%, TIR 
>70%, time with BG < 3.9 mmol/L - <4.0%, time in 
hyperglycemia (> 13.9 mmol/L) <5%, HbA1c < 7.0% 
(13,29). 
Initially, the majority of published studies on 
HCLS were conducted in camps, or in a hospital 
environment under direct 24-hour surveillance by 
medical staff with a small number of participants 
and a short-term follow-up. In a systematic review 
of the literature and meta-analysis of the currently 
available randomized controlled trials, most report-
ed benefits of HCLS use are defined as TIR increased 
by 12.9% (9.02-16.16%, p<0.0001) and episodes of 
hypoglycemia decreased by 2.45% (-3.79 to -1.11%, 
p<0.0003) compared to SAP (21). The improvement 
in regard to HbA1c% vary among different studies. 
Bergenstal et al. reported HbA1c reduction by -0.5% 
(from 7.4% to 6.4%) for a 6-month follow-up in chil-
dren and adults with T1DM started on closed loop 
(30). In a multricenter trial of closed loop, Garg et al. 
registered significantly lower HbA1c (7.7%±0.8% to 
7.1%±0.6%, p<0.001). Key factors for achieving these 
results were increased TIR, lower mean BG levels, 
reduced time spent in hyperglycemia >14 mmol/L 
(from 24.9%±13.5% to 22.8%±8.9%, p=0.01) and hy-
poglycemia (from 6.4%±4.3% to 3.4%±2.1%, p<0.001) 
(31). 
In Korean children with T1DM with similar 
basal HbA1c levels, Choi et al. reported improved 
metabolic control among DIY users (6.8% vs 6.3%, 
p<0.001). In the current study, baseline HbA1c was 
slightly better than the 6th month levels (6.3% vs 
6.5%, p>0.05) and no change in TIR was found at 
the 6th month. Limitation of the current study that 
may partly explain otherwise excellent results is the 
small number of participants with excellent initial 
metabolic control. Despite of the tight initial control 
of DIY group, time spent in hypoglycemia decreas-
es further with 1.3% (from 5% to 3.7%, NS) and time 
spent in hypeglycemia >14 mmol/L dropped down 
by 0.6% (2.7% to 2.1%, NS). These results are similar 
to the reported by Italian and Korean studies (26-28).
One of the main barriers for optimal control 
in children and adolescents with T1DM is the fear 
of severe hypoglycemia (FOH), especially in families 
with a toddler. Some studies show that FOH is not al-
ways associated with an experienced episode (32, 33). 
Many trials have proven that HCLS significantly re-
duce the time spent below 3.9 mmol/L, both at night 
and day time, regardless of the home or supervised 
conditions (22-23, 34-37). The safety and feasibility 
of HCLS in younger T1DM children (5-9 years) were 
demonstrated in a open-label, randomized, crossover 
study done by Del Favero et al. (37). The data showed 
that children using closed loops had a threefold re-
duction of time in hypoglycemia at the cost of high-
er mean BGLs and decreased TIR. Our data confirm 
less time spent below 3.9 mmol/L in the DIY group, 
especially at baseline, in comparison with SAP (5% vs 
12.5%, p=0.055), and no episodes of severe hypogly-
cemia occurred. We explain the improved time with 
BG <3.9 mmol/L in the SAP group (12.5% vs 4.2%, 
p=0.0001) with the more intensive medical advice by 
email and strict follow-up during the study. 
The latest data about the effects of chronic hy-
perglycemia and glucose variability shows associa-
tion with reduced volumes of white and gray matter 
in brain regions involved in  sensory-motor and cog-
nitive functions (38). Also asymptomatic high BGLs 
lead to alterations in electrical brain activity (39). In 
this context, reduced time in hyperglycemia is as im-
portant as time below 3.9 mmol/L. Most of the stud-
ies reported reducing time in hyperglycemia with 
different success, especially after the introduction 
of HCLS (33-34). Choi et al. published non-signifi-
cant improvement in this parameter in children with 
T1DM (26-28, 30-31). In the follow-up period, the 
DIY group had threefold decrease in the time with 
hyperglycemia above 14 mmol/L compared to SAP. 
Glucose variability was stable for the entire observa-
tion period in the current study, and we did not find 
significant difference between both groups.
The disadvantages of most of the studies pub-
lished so far are the small number of participants and 
the short observation periods. When we are discuss-
ing benefits of DIYs, in addition to the precise and 
smart algorithm, we should take into consideration 
the social and economic factors such as: parents‘ ed-
ucation, family environment, self-financing of treat-
ment, which may lead to stricter adherence to the 
therapy and higher goals for the control explaining 
at least partially the excellent diabetes control results. 
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CONCLUSION 
DIY unregistered loop systems show promis-
ing results for better metabolic control without in-
creasing the risk of severe hypoglycemia and dia-
betic ketoacidosis (DKA) at least in terms of mean 
BGLs. Further impact consists of consumed fat/pro-
tein, insulin dose, macro- and microvascular compli-
cations. Longer-term registry data and randomized 
studies are needed to further characterize the safe-
ty and efficacy of automatic insulin delivery systems. 
More research is needed to inform policy and prac-
tice in regard to DIY’s. 
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